Samsung Enters Oncology as Trastuzumab Accepted For EU Review
Samsung Bioepis's trastuzumab has become the South Korean company’s fifth biosimilar candidate to be filed for approval in Europe and also marks its planned entry into the oncology sector in the region.
You may also be interested in...
Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners will initially focus on acute pancreatitis and jointly develop Takeda's preclinical candidate in the segment.
For the South Korean pharma industry, 2016 was largely about major global advances for a wide range of biosimilars, accompanied but some setbacks in the area of novel drug development.
India’s leading biologics company Biocon has said it expects its first biosimilar products to be launched in the European market by early 2018 and is bullish on both its plans in the sector and earnings prospects after reporting quarterly net profit soared by a better than expected 52%.